Friday, July 10, 2026

pharma · Cancer Anorexia · ARTL

ARTELO BIOSCIENCES

Artelo Biosciences is a pharma organization headquartered in La Jolla, USA. It trades on NYSE under ticker ARTL. Primary therapeutic focus areas include Cancer Anorexia. NovaPharmaNews links 1 clinical program(s), 0 drug

La Jolla, USA HQ
2017 Founded
16 Employees
Public company Type
ARTL · NYSE Ticker
Company details
Status
Public
HQ
La Jolla, USA
Founded
2017
Employees
16
Programs
1
Drugs
1
Patents
2
Clinical program

ART27.13-100

Phase 2 · small molecule · Cancer Anorexia

ART27.13-100 for Cancer Anorexia is a Phase 2 program (small_molecule) at ARTELO BIOSCIENCES, INC. with 1 ClinicalTrials.gov record(s).

← All ARTELO BIOSCIENCES, INC. projects Phase 2 small molecule active

Internal code ART27.13-100

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
ARTELO BIOSCIENCES, INC.
Phase
Phase 2
Modality
small_molecule
Indication
Cancer Anorexia
Status
active
Trials
1

Clinical trials